Pharmaceuticals, Biotechnology and Life Sciences
Tiziana Life Sciences a cancer drugs making focused clinical stage biotechnology company got approval in Israel to start testing inhibitor of cell cycle dependent kinases (CDKs), milciclib in a phase II clinical trial.
Amryt, the pharmaceutical company focused on treatments for rare and orphan diseases, has enroled first patient into “EASE”, the company’s pivotal Phase 3 clinical trial, which is evaluating AP101 as a potential treatment for the rare, genetic skin disorder, Epidermolysis Bullosa (“EB”).
Europe’s drugmakers pushed for a decision as early as June on the new location for the headquarters of the bloc’s medicines watchdog, which will relocate from London after Britain’s decision to leave the EU.
European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the marketing authorization of Sanofi and Regeneron Pharmaceuticals joint developed product Kevzara (sarilumab), recommending its approval for use in adult patients with moderately to severely active rheumatoid arthritis.
BD (Becton, Dickinson and Company) will acquire Bard, a medical technology company focused on vascular, urology, oncology and surgical specialty products for $24 billion and appoint Tom Polen as new president of BD.
Allergan will collaborate with Target PharmaSolutions on its five-year longitudinal observational study that looks at patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).
ThromboGenics will pay preclinical milestone to Bicycle Therapeutics in connection with the advancement of a Bicycle (bicyclic peptide) into preclinical development for the treatment of diabetic macular edema.
Redx Pharma has a new Chairman of the Board of Directors and a Non-Executive Director of the company.
Oxford BioDynamics and its scientific advisory panel member, Dr Claudio Carini will be joining Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium as a member of the Cancer, Inflammation & Immunity, and Neuroscience Steering Committees, the company said Thursday.
Forward Pharma has reported financial results for the year ended December 31, 2016.